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suMMARY – Glucocorticoid therapy is the most common cause of secondary osteoporosis and 
the leading iatrogenic cause of the disease. often, the presenting manifestation is fracture, which 
occurs in 30% to 50% of patients receiving long-term glucocorticoid therapy. Glucocorticoid-induced 
osteoporosis predominantly affects regions of the skeleton that have abundant cancellous bone such 
as lumbar spine and proximal femur. progress has been made in clarifying the pathophysiological 
mechanisms that result in glucocorticoid-induced osteoporosis. Although the options for prevention 
and treatment of glucocorticoid-induced osteoporosis continue to expand, provider compliance with 
preventive measures remains suboptimal.
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Introduction
synthetic glucocorticoids (GC) are used in a wide 
variety of disorders, including autoimmune, pulmo-
nary and gastrointestinal diseases, as well as in pa-
tients following organ transplantation and those with 
malignancies. Although the indications for glucocor-
ticoids in these various conditions are clear, their use 
is fraught with a host of potential side effects. The use 
of GC, however, is associated with a variety of ad-
verse effects, including development of osteoporosis 
and fractures1. in patients who have received GCs for 
longer than six months, the estimated glucocorticoid-
induced osteoporosis (Gio) frequency is 50%2. one-
third to one-half of long-term GC users may develop 
fractures. Furthermore, the risk of fractures strongly 
correlates with the daily and cumulative dose of GC 
and does not seem to correlate with the specific under-
lying disease3. The underlying diseases for which GCs 
are prescribed, however, usually carry a risk of osteo-
porosis. skeletal mass is a reflection of the relative 
activities of bone-synthesizing osteoblasts and bone-
resorbing osteoclasts. When the activity of osteoclasts 
supersedes that of osteoblasts, bone loss occurs, which, 
if profound, eventuates into osteoporosis4. Although 
all patients with osteoporosis are predisposed to frac-
tures, the causes of osteoporosis are many, the most 
common attending menopause. estrogen deficiency 
typically prompts a high-turnover form of osteoporo-
sis in which both bone formation and bone resorption 
are accelerated, but the relative activity of osteoclasts 
is greater than that of osteoblasts5,6. Thus, suppression 
of osteoclasts using hormone replacement therapy was 
the standard of care for decades. This article focus-
es on the cellular aspects of glucocorticoid action in 
bone, highlighting the mechanisms that are respon-
sible for bone loss. We also review current guidelines 
and therapeutic approaches for the prevention and 
treatment of Gio.
Glucocorticoid-Induced Osteoporosis
The most common secondary form of osteoporo-
sis is that induced by GC, but the skeletal dynam-
ics of Gio is distinctly different from that associated 
with estrogen deprivation. Whereas bone formation 
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is enhanced following menopause, the inhibition of 
osteoblasts by GC is a major cause of progressive bone 
loss7-10. The dynamics of bone resorption under the 
influence of GCs is, however, more complex. upon 
initiation of GC therapy, bone resorption is acceler-
ated. The fact that administration of low-dose GC 
to healthy women immediately suppresses bone deg-
radation, as determined by urinary excretion of free 
deoxypyridinoline11, suggests that the early accelera-
tion of bone resorption observed during treatment of 
patients with osteoporosis may represent persistence 
of the effects of osteoclast-activating inflammatory 
cytokines12-14. it is during this early stage in the natu-
ral history of Gio that the combination of reduced 
bone formation and accelerated bone resorption yields 
the most profound bone loss15,16. in fact, during long-
term therapeutic exposure to steroids, bone resorption 
changes from accelerated to diminished, likely due to 
direct suppression of osteoclasts via inhibition of cal-
pain 617,18. supporting this contention, prolonged glu-
cocorticoid treatment dampens expression of the key 
osteoclastogenic transcription factor, nuclear factor 
of activated t cells c119. in contrast to high-turnover 
postmenopausal osteoporosis, chronic Gio is, there-
fore, a low-turnover form of the disease in which both 
bone formation and bone resorption are suppressed, 
although formation is suppressed more than resorp-
tion. importantly, the efficacy of bisphosphonates in 
preventing bone loss is substantially greater in the set-
ting of high-turnover as compared with low-turnover 
osteoporosis20.
Clinical assessment of fracture risk typically in-
volves densitometric measurement of bone mass. den-
sitometric analysis, however, does not consider another 
critical component of skeletal integrity, namely, bone 
quality, which is the relationship of bone mass to bio-
mechanical strength21. skeletal remodeling is the key 
event regulating bone mass and likely bone quality21. 
This ever occurring process is characterized by teth-
ering of the activities of bone resorption and forma-
tion. Remodeling is initiated by osteoclast activity. in 
consequence, arrested resorption dampens formation. 
GCs suppress osteoblasts directly and probably by 
inhibiting remodeling17. perhaps the most important 
function of skeletal remodeling, however, is to replace 
effete bone with new bone21. Thus, arrested skeletal re-
modeling, which is exemplified by the adynamic form 
of renal osteodystrophy, diminishes bone quality and 
disassociates bone mass from structural stability21,22. 
long-established Gio reflects not only diminished 
bone mass but also impaired bone quality23.
Treatment of Glucocorticoid Induced 
Osteoporosis
Given the skeletal dynamics of Gio, its treatment 
is complex. Because GCs induce an overall negative 
calcium balance, adequate calcium and vitamin d 
supplementation is important. A Cochrane database 
Meta-Analysis concludes that calcium and vitamin d 
supplementation should be started in all patients who 
are administered GCs because of their low toxicity, 
low cost and the possible benefit in terms of fracture 
risk24. Vitamin d is a hormone that increases intesti-
nal calcium absorption and increases its reabsorption 
in distal renal tubules. Antiresorptive therapy alone 
is logical within the first year or two of GC adminis-
tration, whereas osteoclast activity is accelerated, and 
increased bone mass appears to compensate for altered 
bone quality. in the chronic low-turnover phase of os-
teoporosis, steroids continue to suppress bone forma-
tion but also directly inhibit osteoclasts, often result-
ing in virtual cessation of skeletal remodeling. Recent 
information suggests that bisphosphonates should be 
used cautiously in patients receiving more prolonged 
GC treatment. specifically, a number of bisphospho-
nate-treated patients in whom osteonecrosis of the jaw 
developed were exposed to systemic steroids25. Fur-
thermore, investigators have reported atypical, poorly 
healing fractures, particularly of the femoral shaft, in 
bisphosphonate treated patients26. interestingly, bone 
biopsies of these individuals often demonstrate sup-
pressed remodeling, and several of the patients were 
receiving GCs27-29.
Caution about the prolonged use of bisphospho-
nates is complemented by the greater success of the 
bone anabolic drug, teriparatide, in terms of increas-
ing bone mineral density and preventing vertebral 
fractures. in a randomized, double-blind trial30, 
teriparatide or alendronate was administered to GC 
treated patients, most of whom were postmenopausal 
women with rheumatic disease. in contrast to the 
suppressive effects experienced by patients receiving 
alendronate, those receiving teriparatide experienced 
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accelerated bone remodeling. in a 36-month continu-
ation study, the anabolic effects of teriparatide per-
sisted, as reflected by increased bone mineral density, 
decreased occurrence of vertebral fractures, and slight 
but significantly sustained increases in markers of 
bone formation31,32. As demonstrated in a recent post 
hoc analysis, the GC dose affects these responses33. The 
results of recent clinical trials indicate that 12-month 
treatment with denosumab, a humanized monoclonal 
antibody targeting the osteoclast stimulating cytokine 
RAnKl, effectively reduces Gio in patients with 
rheumatoid arthritis34. 
Conclusion
Gio is a serious skeletal disorder that is associated 
with fractures. The last decade has seen a considerable 
increase in our knowledge of the epidemiology, mech-
anisms and therapeutic approaches to Gio. Further 
comparative effectiveness studies, which ideally are 
sufficiently large and long enough to fully understand 
the fracture risk at both vertebral and nonvertebral 
sites, are needed to better discern the benefits of anti-
resorptive and anabolic agents in the long-term man-
agement of Gio.
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sažetak
GluKoKoRtiKoidiMA izAzVAnA osteopoRozA 
A. Pranić-Kragić, M. Radić, D. Martinović-Kaliterna i J. Radić
liječenje glukokortikoidima je najčešći uzrok sekundarne osteoporoze i vodeći jatrogeni uzrok bolesti. učestala ma-
nifestacija je prijelom koji se javlja u 30% do 50% bolesnika koji su uzimali dugotrajnu glukokortikoidnu terapiju. Gluko-
kortikoidima izazvana osteoporoza uglavnom utječe na trabekularnu kost, kao što je lumbalna kralježnica i proksimalni 
dio bedrene kosti. ostvaren je napredak u razjašnjavanju patofizioloških mehanizama koji rezultiraju glukokortikoidima 
izazvanom osteoporozom. iako su mogućnosti za prevenciju i liječenje glukokortikoidima izazvane osteoporoze sve veće, 
dosadašnje preventivne mjere kao i liječenje su nedostatni.
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